drugset / Trial / NCT04352933

PROLIFIC ChemoprophylaxisTrial (COVID-19)

NCT04352933

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The number of confirmed cases of COVID-19 infectious disease arising from the SARS-CoV-2 coronavirus is rising substantially and rapidly, with the potential to overwhelm the ability of the entire National Health Service (NHS) to cope with the increased demand. The availability of personal protective equipment is limited and reports of high risk procedures such as aerosol generating procedures (e.g. intubation for the sickest patients) is a source of great concern for infection transmission. Frontline NHS staff with direct patient contact have the highest likelihood of exposure to SARS-CoV-2 and development of COVID-19 disease. Efforts to protect these workers from development of COVID-19, using drugs to prevent the disease, require urgent evaluation.

Timeline

Start
2020-05-11
Primary completion
2020-10-31
Completion
2021-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydroxychloroquine Small molecule 200 mg Oral
Comparator Hydroxychloroquine Small molecule 400 mg Oral

Indications